360 High-Risk Vulnerability Immunization Tool V2.0 vs Sophos Endpoint: Side-by-Side Comparison (2026)

360 High-Risk Vulnerability Immunization Tool V2.0: Tool that immunizes Windows systems against critical vulnerabilities. built by 360 Security Group (Qihoo 360). Core capabilities include Remote desktop vulnerability immunization (CVE-2019-0708, CVE-2019-1181, CVE-2019-1182), MS17-010 SMB vulnerability protection against ransomware, Meltdown CPU vulnerability mitigation..

Sophos Endpoint: AI-powered endpoint security with prevention-first approach and EDR capabilities. built by Sophos. Core capabilities include Deep learning AI models for threat detection and prevention, CryptoGuard anti-ransomware with automatic file reversion and MBR protection, Endpoint detection and response (EDR) for threat hunting and investigation..

Both serve the Endpoint Protection Platform market but differ in approach, feature depth, and target audience.

360 High-Risk Vulnerability Immunization Tool V2.0 differentiates with Remote desktop vulnerability immunization (CVE-2019-0708, CVE-2019-1181, CVE-2019-1182), MS17-010 SMB vulnerability protection against ransomware, Meltdown CPU vulnerability mitigation. Sophos Endpoint differentiates with Deep learning AI models for threat detection and prevention, CryptoGuard anti-ransomware with automatic file reversion and MBR protection, Endpoint detection and response (EDR) for threat hunting and investigation.

360 High-Risk Vulnerability Immunization Tool V2.0 is developed by 360 Security Group (Qihoo 360). Sophos Endpoint is developed by Sophos. Vendor maturity, funding stage, and team size can be important factors when evaluating long-term viability and support quality.

360 High-Risk Vulnerability Immunization Tool V2.0 and Sophos Endpoint serve similar Endpoint Protection Platform use cases: both are Endpoint Protection Platform tools. Review the feature comparison above to determine which fits your requirements.